论文部分内容阅读
目的探讨阿托伐他汀对尿毒症非透析患者白细胞介素-6(interleukin-6,IL-6)和高敏C反应蛋白(highsensitivity C-reactive protein,hs-CRP)的影响。方法 72例尿毒症非透析患者随机分成他汀治疗组39例和常规治疗组33例,同期20例体检健康者为对照组,他汀治疗组每晚口服阿托伐他汀20mg,常规治疗组不给予调酯药,观察治疗组治疗前、治疗后12,24周空腹血清IL-6和hs-CRP的变化,并与对照组进行比较。结果与对照组比较,治疗前他汀治疗组与常规治疗组血清IL-6和hs-CRP水平明显升高(P<0.05),血浆前白蛋白、白蛋白、血红蛋白均明显降低(P<0.05);治疗12周后,他汀治疗组IL-6和hs-CRP水平较治疗前下降(P<0.05),治疗24周后较治疗12周后明显下降(P<0.05);他汀治疗组血浆前白蛋白、白蛋白、血红蛋白高于治疗前及同期常规治疗组(P<0.05);血肌酐、尿素氮低于治疗前及同期常规治疗组(P<0.05)。结论应用阿托伐他汀可抑制尿毒症非透析患者的微炎症反应,改善患者营养状态。
Objective To investigate the effects of atorvastatin on interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) in uremic patients without dialysis. Methods Seventy-two patients with uremia without dialysis were randomly divided into statin treatment group (n = 39) and conventional treatment group (n = 33). At the same period, 20 healthy volunteers were taken as control group. Atorvastatin group Esophageal drugs were used to observe the changes of fasting serum IL-6 and hs-CRP in the treatment group before and 12, 24 weeks after treatment, and compared with the control group. Results Compared with the control group, the levels of serum IL-6 and hs-CRP were significantly increased (P <0.05) and the contents of prealbumin, albumin and hemoglobin were significantly decreased in the statin treatment group and conventional treatment group before treatment (P <0.05) (P <0.05). After 12 weeks of treatment, the levels of IL-6 and hs-CRP in statin group decreased significantly (P <0.05) (P <0.05). Serum creatinine and blood urea nitrogen were lower than those of the conventional treatment group before and during the same period (P <0.05). Conclusions Atorvastatin can inhibit the microinflammatory reaction in uremic patients without dialysis and improve the nutritional status of patients.